Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma

Inclusion Criteria: * Patients much have histologically confirmed adenocarcinoma of the colon or rectum. * Patients must have measurable recurrence or metastases in the liver and/or lungs. * Patients must have prior chemotherapy for advanced colorectal cancer and have previously received both an oxaliplatin and an irinotecan based regimen. * Age \> 18 years. * Life expectancy greater than 4 weeks. * ECOG performance status \<3. * Patients must have normal organ and marrow function. * Patients must be able to swallow capsules. * Patients must be able to understand and willing to sign a written informed consent document. * Patients are included regardless of KRAS/BRAF status. Exclusion Criteria: * Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. * Patients may not be receiving any other investigational agent. * Patients with know brain metastases should be excluded from this clinical trial because they often develop progressive neurological dysfunction that would confound the evaluation of neurologic and other adverse events. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to quinacrine, capecitabine or fluorouracil. * The concomitant use of quinacrine and primaquine is contraindicated. * Uncontrolled intercurrent illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study. * Patients with a baseline creatinine clearance of \< 50 mL/min. * Patients must be currently not treated with quinacrine or drugs related to quinacrine. * Patients who require anti-arrhythmic treatment with amiodarone or any drug with a quinidine-like effect on the heart or who have history of a malignant ventricular arrhythmia unless they have a functioning automatic implantable cardio defibrillator implanted. * Patients who have a history of noninfectious hepatitis or alcoholism. * Patients with a lifetime history of porphyria or psoriasis because it can exacerbate these conditions. * Patients with documented glucose-6-phosphate dehydrogenase deficiency. * Patients with a lifetime history of seizure disorder. * Patients with a lifetime history of dermatitis as an allergic/toxic reaction to any medication. * Patients with know dihydropyrimidine dehydrogenase deficiency.